NASDAQ: ARYDArya Sciences Acquisition Corp Iv Stock
$10.04+0.00 (+0%)
Updated Dec 8, 2022
ARYD Price
$10.04
Fair Value Price
$10.04
Market Cap
$192.63M
52 Week Low
$9.70
52 Week High
$10.05
P/E
100.4x
P/B
-23.02x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$1.68M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.03
Operating Cash Flow
-$558k
Beta
0.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ARYD Overview
ARYA Sciences Acquisition Corp IV is a "blank check" company formed to effect mergers, capital stock exchanges asset acquisitions, stock purchases, reorganizations, or similar business combinations. The Company targets the healthcare and healthcare-related sectors. ARYA Sciences Acquisition was incorporated in 2020 and is based in New York, NY.
Zen Score
–
Industry Average (9)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ARYD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ARYD ($10.04) is undervalued by 0% relative to our estimate of its Fair Value price of $10.04 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ARYD ($10.04) is not significantly undervalued (0%) relative to our estimate of its Fair Value price of $10.04 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ARYD is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more ARYD due diligence checks available for Premium users.
Be the first to know about important ARYD news, forecast changes, insider trades & much more!
ARYD News
Valuation
ARYD fair value
Fair Value of ARYD stock based on Discounted Cash Flow (DCF)
Price
$10.04
Fair Value
$10.04
Undervalued by
0.00%
ARYD ($10.04) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ARYD ($10.04) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ARYD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
100.4x
Industry
18.67x
Market
21.39x
ARYD is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ARYD is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
ARYD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-23.02x
Industry
-35.17x
ARYD's financial health
Profit margin
Revenue
$0.0
Net Income
$3.2M
Profit Margin
0%
ARYD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$150.6M
Liabilities
$8.6M
Debt to equity
-1.03
ARYD's short-term liabilities ($6.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARYD's long-term liabilities ($2.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARYD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ARYD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$26.4k
Investing
$0.0
Financing
$0.0
ARYD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ARYD vs Shell Company Stocks
Arya Sciences Acquisition Iv Stock FAQ
©2022 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.